7 recruiting, 4 active not recruiting, 1 not yet recruiting. 9 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 7, Active not recruiting 2 |
| Phase 1 | 3 | Active not recruiting 2, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow JS207: new trials by email Literature Review of JS207 trials Research Report on JS207
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer JS207, JS007, Toripalimab - Hepatocellular Carcinoma | Phase 3 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 560 | 2026-10-08 | 2026-09-16 |
| JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma JS207, Paclitaxel, Capecitabine - Recurrent/ Metastatic NPC | Phase 2 | Recruiting | Chinese University of Hong Kong | 49 | 2026-06-29 | 2026-07-13 |
| JS212 Combination Therapies in Metastatic Colorectal Cancer JS212, Capecitabine, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 80 | 2026-04-25 | 2026-05-05 |
| A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors 7MW3711, JS207, Cisplatin - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | 280 | 2026-02-11 | 2026-03-12 |
| JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC JS207, Pemetrexed injection, Platinum - Non-small Cell Lung Cancer | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 69 | 2025-06-19 | 2026-08-04 |
| JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma JS207, JS007 - Hepatocellular Carcinoma | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 72 | 2025-05-29 | 2025-07-02 |
| JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC Paclitaxel + Carboplatin/cisplatin for squamous cell carcinoma and pemetrexed + carboplatin/cisplatin for non-squamous cell carcinoma, surgery, Radiochemotherapy - NSCLC | Phase 2 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-05-20 | 2026-07-27 |
| A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer JS207, JS015, Capecitabine - Advanced Colorectal Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 60 | 2025-04-23 | 2025-06-24 |
| Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy JS207, Pemetrexed, Carboplatin or cisplatin - Non-squamous Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Junshi Bioscience Co., Ltd. | 78 | 2025-03-30 | 2026-05-18 |
| Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors WJ47156, JS001+Bevacizumab, JS207 - Advanced Malignant Solid Tumors | Phase 1 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 59 | 2024-10-23 | 2026-07-07 |
| The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor JS207 - Advanced Malignant Tumor | Phase 1 | Active not recruiting | Shanghai Junshi Bioscience Co., Ltd. | 98 | 2023-09-26 | 2026-07-02 |
| Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy Dalpiciclib, Pyrotinib, SHR-A1811 - Breast Neoplasm, Breast Cancer | Phase 2 | Recruiting | Fudan University | 716 | 2022-11-01 | 2026-05-28 |
Carcinoma, Hepatocellular (2) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Shanghai Junshi Bioscience Co., Ltd. (9) · Chinese University of Hong Kong (1) · Fudan University (1) · Mabwell (Shanghai) Bioscience Co., Ltd. (1)
China (11) · Australia (1) · Hong Kong (1)
Weihua Wang, Doctor (2) · Jia Fan, Ph.D. (1) · Zhenyu Xu, Doctor (1) · Zhimin Shao, Professor (1)